They work by binding to the inhibitory PD-1 receptor on T cells and PD-L1 on tumor cells, respectively, thus disrupting the PD-1:PD-L1 interaction and reactivating the anti-tumor T-cell response. This evidence concerns the gene CD274 and neoplasm.